[Skip to Content]
[Skip to Content Landing]
December 12, 2001

Cardiovascular Events and COX-2 Inhibitors

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(22):2808-2813. doi:10.1001/jama.286.22.2808

To the Editor: A significant part of the meta-analysis by Dr Mukherjee and colleagues1 involves data from the CLASS study.2 However, the 800 mg per day dose of celecoxib used in CLASS is not recommended for either OA or RA.3 Few practitioners actually use celecoxib at that dosage, so the "real world" significance of this meta-analysis is dubious.